Neuronal potassium channel openers

I. Introduction

Neuronal potassium (K⁺) channel openers are pharmacological agents that enhance the activity of potassium channels located in neuronal membranes. By increasing K⁺ efflux, these drugs hyperpolarize the neuronal membrane, leading to decreased neuronal excitability. This mechanism is relevant in epilepsy, neuropathic pain, multiple sclerosis, and other neurological disorders involving abnormal neuronal firing or hyperexcitability.

Neuronal K⁺ channel openers are part of a broader class of ion channel modulators and often target voltage-gated (Kv), calcium-activated (KCa), ATP-sensitive (KATP), or two-pore domain (K2P) potassium channels. Their use is being actively researched in both central nervous system (CNS) and peripheral nervous system (PNS) disorders, with a small number of agents approved and others in development.

---

II. Mechanism of Action

Neuronal potassium channel openers bind to specific subtypes of K⁺ channels expressed in neurons. These channels are responsible for repolarizing the membrane after action potentials and maintaining resting membrane potential.

By opening these channels:

• K⁺ exits the cell

• The membrane potential becomes more negative

• Threshold for depolarization increases

• Neurons become less excitable

This is beneficial in conditions such as:

• Epilepsy, where neurons fire excessively

• Neuropathic pain, where peripheral nerves are sensitized

• Spasticity, where spinal circuits are hyperactive

---

III. Classification of Neuronal Potassium Channels Targeted

1. Voltage-gated K⁺ channels (Kv)

   • Subfamilies: Kv1–Kv12

   • Critical in action potential repolarization

   • Examples: Kv7.2–7.5 (KCNQ channels)

2. Calcium-activated K⁺ channels (KCa)

   • Activated by intracellular calcium

   • Example: KCa1.1 (BK channel), involved in synaptic activity

3. ATP-sensitive K⁺ channels (KATP)

   • Link cellular metabolism to excitability

   • Open during ATP depletion

4. Two-pore domain K⁺ channels (K2P)

   • Maintain resting membrane potential

   • Examples: TREK-1, TASK-3

---

IV. Representative Drugs and Compounds

1. Retigabine (Ezogabine)

• Type: Kv7.2–7.5 (KCNQ2–5) opener

• Indication: Adjunctive treatment for partial-onset seizures in epilepsy

• Mechanism: Enhances M-current (Kv7), reducing neuronal excitability

• Dose: 600–1200 mg/day in divided doses

• Discontinued: Withdrawn in 2017 due to retinal pigmentation and skin discoloration

• Adverse Effects: Urinary retention, dizziness, blue skin, QT prolongation

2. Flupirtine

• Type: Kv7 channel opener and NMDA receptor modulator

• Indication: Non-opioid analgesic in Europe (withdrawn)

• Use: Neuropathic pain, fibromyalgia, tension headache

• Withdrawal: Hepatotoxicity concerns

• Status: No longer available in the EU since 2018

3. Clemizole derivatives (e.g., VX-765)

• Mechanism: Potassium channel modulation (Kv7) with anti-seizure properties

• Indication: Investigational for Dravet syndrome, rare epilepsies

• Stage: Preclinical and Phase I

4. BMS-204352 (Maxipost)

• Type: KCa1.1 (BK channel) opener

• Mechanism: Enhances calcium-activated K⁺ currents

• Use: Investigated for stroke, Alzheimer’s disease

• Status: Development discontinued; research ongoing in cognition

5. Minoxidil

• Type: KATP channel opener

• Main use: Antihypertensive, hair growth (topical)

• CNS relevance: Experimental use for neuroprotection; poor BBB penetration

6. Cromakalim

• Type: KATP channel opener

• Research: Neuroprotective potential in ischemia

• Not used clinically in CNS conditions due to systemic side effects

---

V. Experimental and Developmental Agents

Compound	Target K⁺ Channel	Indications Studied	Status
XEN1101	Kv7.2–7.5	Focal epilepsy, major depressive disorder	Phase II/III
ICA-27243	Kv7.2/7.3	Anticonvulsant	Preclinical
ML213, ML252, ML308	Kv7.2 modulators	Research tools	Preclinical models
BMS-204352	KCa1.1 (BK)	Alzheimer’s, stroke	Discontinued Phase II
Retigabine derivatives	Kv7.2–7.5	Neuropathic pain, epilepsy	Investigational

VI. Indications and Clinical Applications

1. Epilepsy

   • Kv7 openers reduce action potential firing

   • Retigabine showed efficacy in partial seizures

   • XEN1101 promising for drug-resistant epilepsy

2. Neuropathic Pain

   • K⁺ channel openers dampen aberrant sensory input

   • Flupirtine previously used for musculoskeletal and neurogenic pain

3. Multiple Sclerosis (MS) and Spasticity

   • Suppression of spinal neuron excitability

   • Some K⁺ channel modulators being tested in animal MS models

4. Cognitive Disorders and Stroke

   • KCa and K2P channels modulated in cerebral ischemia

   • BMS-204352 studied for neuroprotection and memory

5. Neurodegenerative Diseases

   • Parkinson’s and Alzheimer’s disease models show altered K⁺ channel expression

   • Modulation under investigation as a neuroprotective strategy

---

VII. Pharmacological Properties and Administration

Drug	Route	Bioavailability	BBB Penetration	Protein Binding	Metabolism
Retigabine	Oral	~60%	High	80%	Hepatic (glucuronidation)
Flupirtine	Oral	~90%	Moderate	80%	Hepatic (CYP enzymes)
XEN1101	Oral	Data limited	Yes (based on design)	Unknown	Investigational

VIII. Side Effects and Safety Considerations

1. Retigabine

   • Retinal and skin pigmentation

   • Blue discoloration of skin

   • Urinary retention

   • QT prolongation

2. Flupirtine

   • Hepatotoxicity (major reason for market withdrawal)

   • Sedation, dizziness

3. Others (XEN1101)

   • Adverse effect profile under evaluation

   • No pigmentation issues reported to date

---

IX. Drug Interactions

• Retigabine:

  • Minimal CYP450 interaction

  • Additive effects with other CNS depressants

  • May interact with digoxin and lamotrigine (increased levels)

• Flupirtine:

  • Potential CYP-mediated interactions

  • Increased risk of liver injury when combined with other hepatotoxic agents

• XEN1101:

  • Drug–drug interaction profile under investigation

---

X. Contraindications and Precautions

• Retigabine:

  • Avoid in patients with retinal diseases, prolonged QT, or urinary retention

  • Monitor for signs of skin/eye discoloration

• Flupirtine:

  • Contraindicated in patients with liver disease

  • Use limited to short-term (<14 days) when it was on market

• Experimental agents:

  • Require careful evaluation in clinical trials

---

XI. Research Directions and Emerging Insights

1. Kv7 Channel Modulators:

   • Highly selective Kv7.2–7.5 openers are in development to reduce retinal risks

   • XEN1101 may become the first new Kv7 drug since Retigabine

2. BK Channel Activation:

   • Shown to reduce neuroinflammation and support hippocampal function

   • Targets Alzheimer's and stroke recovery

3. KATP Channels in Neuroprotection:

   • Role in ischemia-reperfusion injury

   • Cardiovascular side effects limit CNS use

4. Gene Therapy & Channelopathies:

   • KCNQ2 mutation-related epilepsies may be treatable via targeted K⁺ modulation

   • Potential role in precision medicine

---

XII. Clinical Limitations

• Systemic K⁺ channel openers often cause:

  • Hypotension

  • Sedation

  • Cardiac rhythm disturbances

• CNS-specific delivery is a major formulation challenge

• Retigabine’s failure highlights need for:

  • Selective targeting

  • Avoidance of long-term toxicities

---

XIII. Summary List of Key Neuronal K⁺ Channel Openers

• Approved (Withdrawn):

  • Retigabine (Kv7) – Epilepsy

  • Flupirtine (Kv7) – Analgesia

• Investigational:

• XEN1101 (Kv7) – Epilepsy, MDD

• ICA-27243 (Kv7) – Epilepsy

• BMS-204352 (KCa1.1) – Stroke, Alzheimer’s

• Cromakalim (KATP) – Neuroprotection (experimental)